Jean‐Yves Reginster

Author

Jean‐Yves Reginster

Also Known As

J REGINSTER, J Reginster, J Y Reginster, J. Reginster, J. Y. Reginster, J.-Y.L Reginster, Jean-Yves Reginster, Jean‐Yves Reginster, René Rizzoli, Stuart H. Ralston

223

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

University of Liège Inserm Université Claude Bernard Lyon 1 Hôpital Edouard Herriot Centre Hospitalier Universitaire de Liège

About

Jean‐Yves Reginster is an author at University of Liège specializing in medicine, osteoporosis, and osteoarthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	9	1.5K
2	Orthopaedics	4	5	424
3	Obstetrics	3	4	1.3K
4	Biochemistry	1	1	141
5	Geriatrics	1	1	13

Jean‐Yves Reginster

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Romosozumab in Postmenopausal Women with Low Bone Mineral Density Michael R. McClung, Andreas Grauer, Steven Boonen, New England Journal of Medicine	2014	1.2K
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi, The Lancet Diabetes & Endocrinology Bone DiseaseDenosumab TreatmentBone HealthPhase 3Osteopathy	2017	916
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial Jean‐Yves Reginster, J Badurski, Nicholas Bellamy, Annals of the Rheumatic Diseases	2012	286
Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial André Kahan, Daniel Uebelhart, Florent de Vathaire, Arthritis & Rheumatism	2009	265
Effects of long‐term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five‐year, randomized, placebo‐controlled trial Jean‐Yves Reginster, Dieter Felsenberg, Steven Boonen, Arthritis & Rheumatism	2008	262
Intravenous ibandronate injections in postmenopausal women with osteoporosis: One‐year results from the dosing intravenous administration study Pierre D. Delmas, Silvano Adami, Cezary Strugała, Arthritis & Rheumatism	2006	258
Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk Somnath Sarkar, Jean‐Yves Reginster, Gerald Crans, Journal of Bone and Mineral Research	2004	213
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos, The Lancet Diabetes & Endocrinology Bone DiseaseOsteopathyLoft Extension StudyMedicineGynecology	2019	164
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis Michelle Deberg, A Labasse, Stephan Christgau, Osteoarthritis and Cartilage InflammationRheumatologyRheumatoid DisorderBiochemistryMedicine	2005	141
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies Olivier Bruyère, Karel Pavelká, Lucio C. Rovati, Menopause The Journal of The North American Menopause Society	2004	121

Page 1